|November 2009 · Vol. 21, No. 11
New data enhance our understanding of the effects of some contraceptives and key SERMs on the skeletal health of users
ACOG: Given the efficacy of DMPA, the drug may be a good option in some populations, despite its effects on bone density
New vertebral fractures occurred at a rate of 2.3% among women taking denosumab, versus 7.2% among those taking placebo
Among women who switched from alendronate to denosumab, BMD increased by 1.9% at the hip over 12 months, versus 1.05% in those who continued on alendronate
The combination of bazedoxifene and conjugated equine estrogen increased BMD at the lumbar spine and total hip to a greater degree than placebo did
Dr. Goldstein is Professor of Obstetrics and Gynecology at New York University School of Medicine and Director of Gynecologic Ultrasound and Co-Director of Bone Densitometry at NYU Medical Center in New York City. He serves on the OBG Management Board of Editors.
The author reports that he serves on the advisory boards of Amgen, Boehringer Ingelheim, Depomed, Eli Lilly, and Novo Nordisk. He is a speaker for the Alliance for Bone Health, Eli Lilly, and Warner Chilcott.